Lilly Details 2024 ASCO Annual Meeting Presentations

INDIANAPOLIS, May 23, 2024 – Eli Lilly and Company (NYSE: LLY) has announced plans to present data from various oncology studies at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 31 to June 4 in Chicago. The data will highlight the efficacy and safety of several of their cancer treatments, including Verzenio® (abemaciclib), Retevmo® (selpercatinib), olomorasib (a KRAS G12C inhibitor), and imlunestrant (an oral selective estrogen receptor degrader [SERD]).

Investor Event Details

In addition to the presentations, Lilly will host an investor event to discuss its oncology strategy and pipeline developments. This event will take place on June 2 at 7:30 p.m. CDT and will be accessible via a live webcast on Lilly’s investor website. A replay will also be available.

Key Presentations and Their Highlights

Verzenio (abemaciclib)
1. Phase 3 postMONARCH Study: This late-breaking oral presentation will report outcomes for Verzenio combined with fulvestrant versus placebo plus fulvestrant in HR+, HER2- advanced or metastatic breast cancer patients who experienced disease progression on prior CDK4/6i and endocrine therapy.
2. CYCLONE 2 Study: Data from the phase 3 study exploring Verzenio with abiraterone for metastatic castration-resistant prostate cancer will be presented.
3. MonarchE Trial: Insights into the prognostic utility of ctDNA detection in high-risk early breast cancer treated with adjuvant Verzenio and endocrine therapy will also be shared.

Retevmo (selpercatinib)
1. LIBRETTO-121 Study: Results from this Phase 1/2 study will assess Retevmo's safety and efficacy in pediatric and adolescent patients with advanced solid tumors featuring RET alterations.
2. LIBRETTO-431 Study: Intracranial outcomes of selpercatinib in advanced RET fusion-positive non-small cell lung cancer (NSCLC) will be discussed.
3. Various Tumor Studies: Multiple presentations will examine selpercatinib's efficacy in different tumor types, including non-MTC, RET-mutated tumors, and its impacts on health-related quality of life (HRQoL) and patient-reported tolerability.

Olomorasib (Investigational KRAS G12C inhibitor)
1. Phase 1/2 Study Results: Two oral presentations will reveal updated data on the safety and efficacy of olomorasib combined with pembrolizumab in KRAS G12C-mutant advanced NSCLC, and as a monotherapy for KRAS G12C-mutant advanced solid tumors.

Imlunestrant (Investigational Oral SERD)
1. EMBER Phase 1a/1b Study: Data will be shared on imlunestrant in combination with HER2-directed therapy, with or without abemaciclib, in ER+, HER2+ advanced breast cancer.
2. Endometrial Cancer Study: Results of imlunestrant as a monotherapy and in combination with abemaciclib in endometrioid endometrial cancer (EEC) will also be presented.

About the Medications

Verzenio (abemaciclib)
Verzenio is approved for treating HR+, HER2- breast cancers in various settings and is the only CDK4/6 inhibitor approved for high-risk early breast cancer. It shows deepening benefits beyond the two-year treatment period in the monarchE trial and has demonstrated statistically significant overall survival in metastatic breast cancer in the MONARCH 2 study. Verzenio is administered as an oral tablet twice daily and is approved in over 90 countries.

Retevmo (selpercatinib)
Retevmo is a highly selective RET kinase inhibitor approved for treating several RET-driven cancers, including advanced NSCLC, medullary thyroid cancer, and other solid tumors with RET gene fusions. The drug is taken orally twice daily and has shown significant activity in central nervous system tumors.

Conclusion
Eli Lilly’s upcoming presentations at the ASCO Annual Meeting underscore the company’s ongoing commitment to advancing cancer treatment through innovative therapies. The detailed data on Verzenio, Retevmo, olomorasib, and imlunestrant will offer valuable insights into their potential benefits for various cancer types, demonstrating Lilly’s robust oncology pipeline.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!